AU2002216748A1 - Method of treatment of seborrheic dermatitis - Google Patents

Method of treatment of seborrheic dermatitis

Info

Publication number
AU2002216748A1
AU2002216748A1 AU2002216748A AU1674802A AU2002216748A1 AU 2002216748 A1 AU2002216748 A1 AU 2002216748A1 AU 2002216748 A AU2002216748 A AU 2002216748A AU 1674802 A AU1674802 A AU 1674802A AU 2002216748 A1 AU2002216748 A1 AU 2002216748A1
Authority
AU
Australia
Prior art keywords
lotion
cream
treatment
seborrheic dermatitis
ivermectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002216748A
Inventor
L. Dean Parks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DEAN PARKS DEAN L
Original Assignee
DEAN PARKS DEAN L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DEAN PARKS DEAN L filed Critical DEAN PARKS DEAN L
Publication of AU2002216748A1 publication Critical patent/AU2002216748A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Abstract

A method of treatment of seborrheic dermatitis includes the application, in the form of either a lotion or a cream, of a mixture including a therapeutically effective amount of ivermectin in water in a concentration of about 750 micrograms per milliliter (mcg/ml), in the case of a lotion, and with a pharmaceutically acceptable carrier if used as a cream. Such a lotion or cream is applied nightly for a period of seven days and then employed on a maintenance basis one to four times per month.
AU2002216748A 2000-06-29 2001-06-27 Method of treatment of seborrheic dermatitis Abandoned AU2002216748A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/605747 2000-06-29
US09/605,747 US6319945B1 (en) 2000-06-29 2000-06-29 Method of treatment of seborrheic dermatitis
PCT/US2001/041159 WO2002002056A2 (en) 2000-06-29 2001-06-27 Method of treatment of seborrheic dermatitis

Publications (1)

Publication Number Publication Date
AU2002216748A1 true AU2002216748A1 (en) 2002-01-14

Family

ID=24425042

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002216748A Abandoned AU2002216748A1 (en) 2000-06-29 2001-06-27 Method of treatment of seborrheic dermatitis

Country Status (10)

Country Link
US (2) US6319945B1 (en)
EP (1) EP1294375B1 (en)
JP (1) JP3802485B2 (en)
CN (1) CN1171588C (en)
AT (1) ATE314068T1 (en)
AU (1) AU2002216748A1 (en)
CA (1) CA2384448C (en)
DE (1) DE60116302T2 (en)
ES (1) ES2252312T3 (en)
WO (1) WO2002002056A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399651B1 (en) * 2000-06-29 2002-06-04 L. Dean Parks Method of treating dermatoses using avermectin compound
US7897559B2 (en) * 2000-06-29 2011-03-01 Parks L Dean Dermatological composition and kit containing avermectin compound for treating dermatological conditions
US7217463B2 (en) 2002-06-26 2007-05-15 Avery Dennison Corporation Machine direction oriented polymeric films and methods of making the same
JP5711867B2 (en) * 2003-04-24 2015-05-07 ガルデルマ・ソシエテ・アノニム Use of ivermectin for the treatment of dermatological diseases
FR2854074B1 (en) 2003-04-24 2007-11-23 Galderma Res & Dev USE OF IVERMECTIN FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS
FR2867684B1 (en) * 2004-03-18 2006-05-05 Galderma Sa CREAM GEL CONTAINING IVERMECTIN
FR2894823B1 (en) * 2005-12-20 2008-02-29 Galderma Sa REVERSE EMULSION TYPE COMPOSITION COMPRISING IVERMECTIN AND ITS USES IN COSMETICS AND DERMATOLOGY
CN101466543B (en) 2006-06-14 2014-03-19 艾利丹尼森公司 Conformable and die-cuttable machine direction oriented labelstocks and labels, and process for preparing
AU2007261011B2 (en) 2006-06-20 2012-04-05 Avery Dennison Corporation Multilayered polymeric film for hot melt adhesive labeling and label stock and label thereof
EP2091325B1 (en) 2006-10-12 2014-08-06 Topaz Pharmaceuticals Inc. Shampoo-conditioner formulations comprising an avermectin for elimination of, and prophylaxis against, susceptible and treatment-resistant strains of lice
US8901163B2 (en) 2007-01-03 2014-12-02 Galderma S.A. Method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by insect stings or noxious weeds or plants using avermectin compound
EP2629772B1 (en) 2010-10-20 2016-05-18 Galderma S.A. Ivermectin for use in the treatment of hemorrhoids
EP2629770B1 (en) 2010-10-20 2016-05-25 Galderma S.A. Ivermectin for use in treating otitis externa
US9233117B2 (en) 2013-07-08 2016-01-12 Galderma S. A. Treatment of inflammatory lesions of rosacea with ivermectin
US9782425B2 (en) 2013-07-08 2017-10-10 Galderma S.A. Treatment of papulopustular rosacea with ivermectin
BR112016028445B1 (en) 2014-06-02 2022-05-31 Avery Dennison Corporation Oriented film with abrasion resistance, clarity and conformability, label assembly comprising the film and method for producing a labeled article
CN110604741A (en) * 2018-06-15 2019-12-24 瑞恩生化科技有限公司 Composition for inhibiting skin cell proliferation and application thereof
EP4062907A1 (en) 2021-03-23 2022-09-28 Substipharm Formulation for oral administration of ivermectin and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439924A (en) * 1991-12-23 1995-08-08 Virbac, Inc. Systemic control of parasites
US5877295A (en) * 1992-09-30 1999-03-02 The Center For Blood Research Antibodies which bind a subpopulation of Mac-1 (CD11b/CD18) molecules which mediate neutrophil adhesion to ICAM-1 and fibrinogen
DE4328689A1 (en) * 1993-08-26 1995-03-02 Beiersdorf Ag Method for detecting and counting microorganisms
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US5654312A (en) * 1995-06-07 1997-08-05 Andrulis Pharmaceuticals Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
WO1997044034A1 (en) * 1996-05-20 1997-11-27 Otsuka Pharmaceutical Co., Ltd. Remedy for rosacea
US5952372A (en) * 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
KR100315465B1 (en) * 1998-11-23 2002-02-19 성재갑 Animal Insect Repellent Compositions Containing Water Soluble Polymer and Alcohol

Also Published As

Publication number Publication date
US6433006B2 (en) 2002-08-13
DE60116302D1 (en) 2006-02-02
WO2002002056A3 (en) 2002-03-28
WO2002002056A2 (en) 2002-01-10
EP1294375A4 (en) 2004-06-09
CN1383379A (en) 2002-12-04
US20020019354A1 (en) 2002-02-14
ATE314068T1 (en) 2006-01-15
CN1171588C (en) 2004-10-20
CA2384448A1 (en) 2002-01-10
CA2384448C (en) 2008-09-16
JP3802485B2 (en) 2006-07-26
JP2004501939A (en) 2004-01-22
EP1294375A2 (en) 2003-03-26
US6319945B1 (en) 2001-11-20
DE60116302T2 (en) 2006-08-10
EP1294375B1 (en) 2005-12-28
ES2252312T3 (en) 2006-05-16

Similar Documents

Publication Publication Date Title
AU2002216748A1 (en) Method of treatment of seborrheic dermatitis
NZ318282A (en) Pharmaceutical formulation containing amoxycillin and clavulanate in a weight ratio of 12:1 and 20:1
UA41446C2 (en) Use of fumagilol or its derivatives for preparing drugs intended for treating intestinal infection and pharmaceutical composition
AU6414994A (en) Composition and method for reducing toxicity of biologically-active factors
BR0014512A (en) Topical treatment for streptococcal infections
GR3032251T3 (en) Compositions containing prostaglandin e1 and/or troxerutine complexed with phosphatidylcholine for topical treatment of erectile impotence
KR960700061A (en) PHARMACEUTICAL COMPOSITION FOR TREATING NICOTINE DEPENDENCE
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
AU1809495A (en) Composition and method for preventing and treating inflammation with immunoglobulin a
MX9603596A (en) Prevention and treatment of topical viral infections with perfluoropolyether compounds and compositions including perfluoropolyether compounds.
NZ326345A (en) Composition containing diosgenin
AU629445B2 (en) Improvements in or relating to topical compositions containing 1 alpha 25-dihydroxycholecalciferol
NO955084L (en) Estreno steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
ZA969351B (en) Organic compositions
HUT70521A (en) Process to prepare pharmaceutical comps. again amyloidosis
HUT74460A (en) Pharmaceutical composition for psoriasis treatment
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
AU5521099A (en) Use of lithium gluconate for making a medicine for treating herpes and seborrheic dermatitis
TW238246B (en) Pharmaceutical composition for reducing the renal toxicity and enhancing the effect of antitumor
WO2000019997A8 (en) Controlled release dosage from comprising oxybutynin
ATE209495T1 (en) ANTIATHEROSCLEROTIC AGENTS
CA2100314A1 (en) Pharmaceutical Composition for the Treatment of Chronic Skin Ulcers
NO870001L (en) VEHICLE TO REDUCE THROTTLE OF THERAPAUTIC AND COSMETIC PHARMACOLOGICAL ACTIVE AGENTS THROUGH THE SKIN.
UA15180A (en) Method for conservative treatment of generalized periodontitis